Chengcheng Meng

758 total citations
16 papers, 336 citations indexed

About

Chengcheng Meng is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Chengcheng Meng has authored 16 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Hematology and 4 papers in Genetics. Recurrent topics in Chengcheng Meng's work include Acute Myeloid Leukemia Research (6 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Chengcheng Meng is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Chengcheng Meng collaborates with scholars based in United States, China and Switzerland. Chengcheng Meng's co-authors include Ellen Weisberg, Martin Sattler, James D. Griffin, Sara J. Buhrlage, Jinhua Wang, Nathanael S. Gray, Priscilla L. Yang, Qingwang Liu, Qingsong Liu and Richard M. Stone and has published in prestigious journals such as Journal of Medicinal Chemistry, British Journal of Cancer and Frontiers in Microbiology.

In The Last Decade

Chengcheng Meng

16 papers receiving 333 citations

Peers

Countries citing papers authored by Chengcheng Meng

Since Specialization

Citations

This map shows the geographic impact of Chengcheng Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengcheng Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengcheng Meng more than expected).

Fields of papers citing papers by Chengcheng Meng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengcheng Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengcheng Meng. The network helps show where Chengcheng Meng may publish in the future.

Co-authorship network of co-authors of Chengcheng Meng

This figure shows the co-authorship network connecting the top 25 collaborators of Chengcheng Meng. A scholar is included among the top collaborators of Chengcheng Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengcheng Meng. Chengcheng Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8 2024 ·Journal of Medicinal Chemistry ·Yufeng Xiao, Nikee Awasthee, Yi Liu, Chengcheng Meng, (unknown), (unknown), (unknown), Zongtao Lin, (unknown), Benjamin A. García, Robert Kridel, Daiqing Liao, Guangrong Zheng	8
2	Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma 2024 ·Cancers ·Basudev Chowdhury, Swati Garg, Wei Ni, Martin Sattler, (unknown), Chengcheng Meng, (unknown), Richard M. Stone, William C. Forrester, Edmund Harrington, Sara J. Buhrlage, James D. Griffin, Ellen Weisberg	2
3	HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation 2023 ·Cell chemical biology ·Yufeng Xiao, (unknown), Nikee Awasthee, Chengcheng Meng, Xuan Zhang, Yi Liu, (unknown), Zhiguang Huo, Dongwen Lv, Weizhou Zhang, Mei He, Guangrong Zheng, Daiqing Liao	20
4	Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy 2022 ·Journal of Medical Virology ·(unknown), Mikołaj Słabicki, (unknown), J. J. Patten, Charles Zou, Chengcheng Meng, Brett L. Hurst, Jinhua Wang, Radosław P. Nowak, Priscilla L. Yang, Martin Sattler, Richard M. Stone, James D. Griffin, Nathanael S. Gray, Suryaram Gummuluru, Robert A. Davey, Ellen Weisberg	18
5	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2 2021 ·Leukemia ·Jing Yang, Ellen Weisberg, Xiaoxi Liu, Robert S. Magin, (unknown), Bin Hu, Nathan J. Schauer, Shengzhe Zhang, Ilaria Lamberto, Laura M. Doherty, Chengcheng Meng, Martin Sattler, Lucía Cabal‐Hierro, Eric S. Winer, Richard M. Stone, Jarrod A. Marto, James D. Griffin, Sara J. Buhrlage	19
6	Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia 2020 ·Journal of Cellular and Molecular Medicine ·Ellen Weisberg, Chengcheng Meng, Abigail E. Case, Hong L. Tiv, Prafulla C. Gokhale, Sara J. Buhrlage, Jing Yang, Xiaoxi Liu, Jinhua Wang, Nathanael S. Gray, Sophia Adamia, Martin Sattler, Richard M. Stone, James D. Griffin	19
7	Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia 2020 ·Leukemia ·Ellen Weisberg, Chengcheng Meng, Abigail E. Case, Martin Sattler, Hong L. Tiv, Prafulla C. Gokhale, Sara J. Buhrlage, Jinhua Wang, Nathanael S. Gray, Richard M. Stone, (unknown), Shripad V. Bhagwat, Ramón V. Tiu, Sophia Adamia, James D. Griffin	1
8	Inhibition of the deubiquitinase USP10 induces degradation of SYK 2020 ·British Journal of Cancer ·Jing Yang, Chengcheng Meng, Ellen Weisberg, Abigail E. Case, Ilaria Lamberto, Robert S. Magin, Sophia Adamia, Jinhua Wang, Nathanael S. Gray, (unknown), Richard M. Stone, Martin Sattler, Sara J. Buhrlage, James D. Griffin	22
9	Residues 315 and 369 in HN Protein Contribute to the Thermostability of Newcastle Disease Virus 2020 ·Frontiers in Microbiology ·(unknown), Xiaorong Zhang, Chengcheng Zhang, (unknown), Chengcheng Meng, Mengjiao Guo, Yantao Wu, (unknown)	14
10	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations 2020 ·Journal of Cellular and Molecular Medicine ·Ellen Weisberg, Chengcheng Meng, Abigail E. Case, Hong L. Tiv, Prafulla C. Gokhale, (unknown), Sara J. Buhrlage, Xiaoxi Liu, Jinhua Wang, Nathanael S. Gray, Richard M. Stone, Sophia Adamia, Eric S. Winer, Martin Sattler, James D. Griffin	2
11	Repurposing of Kinase Inhibitors for Treatment of COVID-19 2020 ·Pharmaceutical Research ·Ellen Weisberg, (unknown), Priscilla L. Yang, Martin Sattler, Qingsong Liu, Qingwang Liu, Jinhua Wang, Chengcheng Meng, Sara J. Buhrlage, Nathanael S. Gray, James D. Griffin	97
12	Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM) 2020 ·Cancers ·(unknown), Abigail E. Case, Dalia Larios, (unknown), Chengcheng Meng, (unknown), Ellen Weisberg, Michael J. Poitras, Prafulla C. Gokhale, Cloud P. Paweletz, Klaus Podar, Ravi Salgia, Srinivas Vinod Saladi, James D. Griffin, David A. Frank, Raphael Bueno, Martin Sattler	17
13	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies 2019 ·British Journal of Haematology ·Ellen Weisberg, Chengcheng Meng, Abigail E. Case, Martin Sattler, Hong L. Tiv, Prafulla C. Gokhale, Sara J. Buhrlage, Xiaoxi Liu, Jing Yang, Jinhua Wang, Nathanael S. Gray, Richard M. Stone, Sophia Adamia, Patrice Dubreuil, Sébastien Letard, J D Griffin	37
14	Establishment and application of a multiplex PCR assay for detection of Rhizoctonia cerealis, Bipolaris sorokiniana, and Fusarium spp. in winter wheat 2019 ·Journal of Plant Pathology ·Xiaofeng Sun, Lı Zhang, Chengcheng Meng, (unknown), (unknown), Jinfeng Yu	10
15	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase 2017 ·Oncotarget ·Ellen Weisberg, Alexandre Puissant, Richard M. Stone, Martin Sattler, Sara J. Buhrlage, Jing Yang, Paul W. Manley, Chengcheng Meng, (unknown), John Daley, Suzan Lazo, Renee D. Wright, David M. Weinstock, Amanda L. Christie, Kimberly Stegmaier, James D. Griffin	21
16	The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements 2016 ·Epigenetics & Chromatin ·Elena M. Pugacheva, (unknown), Qiongfang Wu, Jingjing Li, Cheng Chen, Chengcheng Meng, Jian Liu, Susan Robinson, Dmitry Loukinov, Abdelhalim Boukaba, Andrew P. Hutchins, Victor V. Lobanenkov, Alexander Strunnikov	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact